A single lot of acamprosate calcium delayed-release tablets has been recalled after failing dissolution testing, meaning the tablets may not release the active drug the way they are supposed to. The medication is prescribed to help people with alcohol use disorder stay abstinent after they have already stopped drinking.
The recall covers one lot of the 333 mg tablets in 180-count bottles, with an October 2026 expiration date. Mylan initiated the action, which appears in the agency's weekly enforcement listings according to enforcement report tracking. MedicalDaily is not publishing a lot number because the specific code could not be confirmed against a primary FDA record, and printing the wrong one would give patients false reassurance.
Failed dissolution is a quality problem rather than a contamination problem. Nothing harmful was found in the tablets. The concern is that a tablet which does not break down on schedule may deliver less drug into the bloodstream than intended, which for a medication whose entire purpose is maintaining a steady effect is a meaningful gap.
The Quiet Way This Kind of Defect Shows Up
Acamprosate does not produce a sensation a patient can monitor. There is no immediate effect to notice and no withdrawal syndrome if a dose is missed. That makes a subpotent lot unusually hard to detect from the inside.
The drug also builds gradually. Steady-state blood levels are reached within about five days of dosing, and the standard regimen is two 333 mg tablets three times a day. A lot that underdelivers would not announce itself with a single bad day. It would show up, if at all, as cravings creeping back over a week or two.
That is the part worth stating plainly and without blame. If someone taking this medication has felt their footing slip recently, a manufacturing defect is one possible explanation among many, and it is not a personal failure. It is also not something to conclude on one's own. The right move is a conversation with the prescriber or pharmacist, not a self-diagnosis.
Acamprosate is one of three medications approved in the United States for alcohol use disorder, alongside naltrexone and disulfiram. It is not metabolized by the liver, which is why it is often chosen for patients with liver disease. It is contraindicated in severe kidney impairment, since the kidneys clear it.
The prescribing information is explicit that the drug is indicated for maintaining abstinence in patients who are already abstinent when treatment begins, and that it should be part of a comprehensive management program that includes psychosocial support.
Checking a Bottle Without Interrupting Treatment
Patients can find the lot number printed on the pharmacy label or on the manufacturer's bottle. The practical step is to call the dispensing pharmacy, give them the lot and expiration date, and ask them to check it against the current FDA enforcement listing. Pharmacies do this routinely.
If the lot does match, the next step is a replacement fill from a different lot. That substitution does not require a new prescription in most cases.
The important sequencing point is that no one should pause treatment while sorting this out. There is no safety hazard identified in the recalled tablets, only a possibility that they are less effective than intended. Stopping outright removes whatever benefit the medication is providing.
Patients who are uninsured or facing a copay problem on a replacement fill can ask the pharmacy about generic pricing, since acamprosate has been available generically for years and is typically inexpensive. Federally qualified health centers and state-funded substance use treatment programs also dispense these medications, and the Substance Abuse and Mental Health Services Administration maintains a national treatment locator and helpline for people who need to find a prescriber.
The Broader Supply Picture for Addiction Medications
Medications for alcohol use disorder are already underprescribed relative to the number of people who could benefit. A recall affecting even one lot lands on a treatment population that often had to work hard to get the prescription in the first place.
Dissolution failures are among the most common reasons generic tablets are recalled, and they surface through routine stability testing rather than through patient reports. That is the system working as designed. Manufacturers test retained samples over the labeled shelf life, and a lot that drifts out of specification gets pulled.
What the system does not do well is tell individual patients. Recalls at this level are communicated to wholesalers and pharmacies, not through direct consumer notification, which is why many people learn about them from news coverage or not at all.
Anyone who wants to check for future actions can monitor the FDA's recalls and safety alerts page and its weekly enforcement report, which lists affected lot numbers and expiration dates and records the risk classification once the agency assigns one. Quality problems or side effects can be reported through the agency's MedWatch program.
The Next Checkpoints for Patients and Clinicians
Neither Mylan nor the FDA has indicated whether additional lots may be added, and no illnesses have been reported in connection with the recall. Recalls initiated for stability-test failures sometimes expand as testing of adjacent lots continues.
For patients, the practical horizon is short. Check the lot, replace it if it matches, keep taking the medication, and mention any recent change in cravings to the prescriber rather than waiting for a scheduled follow-up if it feels significant.
For clinicians and pharmacies, the useful step is checking dispensing records against the affected lot and flagging patients who received it, particularly those who reported difficulty during the relevant window. MedicalDaily will report any expansion of the recall.
If you are struggling with alcohol use, support is available. The SAMHSA National Helpline is free, confidential, and available around the clock at 1-800-662-4357.
Key Questions Answered
Which product is recalled? One lot of acamprosate calcium delayed-release tablets, 333 mg, in 180-count bottles, with an October 2026 expiration date. Mylan initiated the recall.
What does failed dissolution mean? The tablets did not break down within the required range during laboratory testing. That can mean less of the active drug reaches the bloodstream than intended. It is not a contamination problem.
Should someone stop taking acamprosate? No. There is no safety hazard identified in the recalled tablets, only a possible loss of effectiveness. Stopping removes any benefit the medication is providing. Contact the pharmacy about a replacement fill.
How would a patient know if their tablets underperformed? They likely would not. Acamprosate produces no sensation to monitor and takes about five days to reach steady levels. Any effect would appear gradually as returning cravings, which is worth raising with a prescriber.
How can someone tell whether their bottle is affected? The lot number is printed on the pharmacy label or the manufacturer's bottle. A pharmacist can check it against the current FDA enforcement listing, which records the affected lot and expiration date.
What is acamprosate used for? Maintaining abstinence from alcohol in people with alcohol dependence who are already abstinent when treatment starts. It is meant to be used alongside counseling and other support.
Have any illnesses been reported? No illnesses have been reported in connection with this recall.
